EDAP announces placement of first Sonolith i-sys electroconductive lithotripter in South Africa

NewsGuard 100/100 Score

EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, reported today placement of the first Sonolith i-sys electroconductive lithotripter in South Africa.

Pretoria Urology Hospital (PUH) is the largest private urology hospital in South Africa, entirely dedicated to treating urology disorders ranging from urinary stones to prostate cancer. A medical team of fourteen urologists at PUH is actively focusing on offering best-in-class treatment options to patients and has been using EDAP's Ablatherm-HIFU technology to successfully treat prostate cancer for over a year. More than 600 lithotripsy treatments are performed every year at PUH, together with associated endourology procedures. Sonolith i-sys fully integrated system is the ideal treatment to meet PUH's lithotripsy needs.

Mr. Gary Wachsberger, Director of Intamed, EDAP's distribution partner in South Africa, commented, "We have enjoyed a long term relationship with EDAP to distribute their best-in-class urology devices in South Africa and have successfully introduced the Company's Ablatherm-HIFU device. We are excited to now place the first electroconductive Sonolith i-sys in South Africa. Its compelling efficacy and superiority will allow patients to benefit from the industry leading technology to treat their urinary stones. We are very optimistic about additional placement opportunities for EDAP's range of Sonolith devices."

Marc Oczachowski, Chief Executive Officer of EDAP, added, "We are actively pursuing our global expansion strategy of entering new and growing markets. We are very excited to move forward the entry of EDAP in the major African markets, with the first installation of our innovative and leading integrated lithotripsy system, the Sonolith i-sys. This is another successful milestone in our aggressive strategy to penetrate new markets and take more market share thanks to our unique and fully renewed range of lithotripters."

Marc Oczachowski concluded, "We continue to work actively on pushing forward our regulatory programs in major markets and are on track for Sonolith i-move approvals in the U.S. and major international markets."

Intamed is part of Intamarket Group that has specialized in the distribution of high technology products for more than 35 years. Intamed distributes medical devices and consumables capital medical equipment on behalf of significant international brands to the healthcare industry in South Africa and neighboring countries.

Source:

 EDAP TMS SA

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer